Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (769)	4/18/2008 11:06:39 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

I personally have joined the camp that believes this is a scam company, at least when it comes to Advexin. How about you? I haven't been interested in Advexin, but thought some of their other products, including Ad-mda7 (INGN 241) appeared to have potential. Since I already have a profit on my present position, I am willing to wait for further developments. There are some positive items to consider in spite of all the negative comments from A.F.<g> On Tuesday they announced the appointment of Robert “Bob” Pearson to its board of directors. biz.yahoo.com The "analysts" consensus target for one Yr, is around $8.75, but I would be satisfied with $6 <g> finance.yahoo.com According to the estimates data by Thomson, the loss for 2008 is around $0.57/shr vs. the loss of $0.70/shr in 2007 & for 2009 the estimates are around $0.28/shr on the black column.<g> In February they announced that they started a trial of INGN 225 in patients with metastatic SCLC, supported by $1.3M award from the NCI. biz.yahoo.com In January they sold their shrs of Silence Therapeutics for $7.5M & according to Nance, their partnership with Silence will not be impacted by the sale.They had bought the shrs in July 2005 for around $3M. biz.yahoo.com There are some positive anecdotals items regarding Advexin.<g> Two lung cancer patients who were part of ADVEXIN therapy studies program were featured in the Summer 2004 issue of Conquest magazine, a publication of M. D. Anderson Cancer Center, in connection with reaching their five-year survival anniversary. In addition, a patient with recurrent head and neck cancer who achieved a complete tumor remission on ADVEXIN therapy continued to be disease-free over eight years later while receiving repeated treatments of ADVEXIN therapy. Data from the PI of INGN 241 in patients with solid tumors demonstrated that direct injection of INGN 241 induced programmed cell death in 100% of the tumors treated, even in patients who had failed prior therapy with other anti-cancer drugs. Clinical responses were observed in 44% of the treated lesions, including complete and partial responses in two patients with melanoma. Patients treated with INGN 241 had increases in a subset of T-cells that help to destroy cancer cells, which is consistent with the role of the mda-7 protein as a member of the interleukin family of immune stimulating proteins. Bottom line: It seems that for the time being is best to sell INGN on spikes & try to buy back at lower levels to keep pushing the average share cost down into negative territory.<g> RAGL Bernard